ERBB2 Q709L

CI-VAR-00003580Explore in graph →CIViC 3576

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
ERBB2 Q709L	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID9791 Functional analysis was performed for ERBB2 transmembrane domain (TMD) and juxtamembrane domain (JMD) mutations. The JMD mutation Q709L was expressed in BaF3 cells and showed a significant increase in… (full text at CIViC) PMID 30449325 · Pahuja et al., 2018 · Open in CIViC	civic
Unmapped disease1unmapped disease
ERBB2 Q709L	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID9790 Functional analysis was performed for ERBB2 transmembrane domain (TMD) and juxtamembrane domain (JMD) mutations. The JMD mutation Q709L was expressed in BaF3 cells and showed a significant increase in… (full text at CIViC) PMID 30449325 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.